Dr. Hope Rugo on Safety of Trastuzumab Biosimilar for HER2+ Breast Cancer
October 14th 2016
Hope Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses MYL-1401O, a proposed biosimilar for trastuzumab (Herceptin), in patients with HER2-positive metastatic breast cancer.